BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, Macleod A. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005;:CD003266. [PMID: 16034896 DOI: 10.1002/14651858.CD003266.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016;36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
2 Lea JP, Norris K, Agodoa L. The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. Am J Nephrol 2008;28:732-43. [PMID: 18434712 DOI: 10.1159/000127981] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
3 Galle JC, Addison J, Suranyi MG, Claes K, Di Giulio S, Guerin A, Herlitz H, Kiss I, Farouk M, Manamley N, Wirnsberger G, Winearls C. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study. Nephrol Dial Transplant 2016;31:2073-85. [PMID: 27190334 DOI: 10.1093/ndt/gfw047] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Javidan AN, Shahbazian H, Emami A, Yekaninejad MS, Emami-Razavi H, Farhadkhani M, Ahmadzadeh A, Gorjipour F. Safety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial. Hematol Rep 2014;6:5195. [PMID: 25317316 DOI: 10.4081/hr.2014.5195] [Reference Citation Analysis]
5 Inrig JK, Sapp S, Barnhart H, Patel UD, Reddan D, Singh A, Califf RM, Szczech L. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. Nephrol Dial Transplant 2012;27:3606-14. [PMID: 22573238 DOI: 10.1093/ndt/gfs123] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
6 Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care 2007;1:14. [PMID: 17910755 DOI: 10.1186/1750-4732-1-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
7 Hahn D, Esezobor CI, Elserafy N, Webster AC, Hodson EM. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev 2017;1:CD011690. [PMID: 28066881 DOI: 10.1002/14651858.CD011690.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 de Francisco AL. Individualizing anaemia therapy. NDT Plus 2010;3:519-26. [PMID: 25949459 DOI: 10.1093/ndtplus/sfq164] [Reference Citation Analysis]
9 Mitra PK, Bradley JR. Chronic kidney disease in primary care. J R Soc Med 2007;100:40-5. [PMID: 17197687 DOI: 10.1177/014107680710000115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Mesgarpour B, Heidinger BH, Schwameis M, Kienbacher C, Walsh C, Schmitz S, Herkner H. Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis. Intensive Care Med 2013;39:1896-908. [PMID: 23928897 DOI: 10.1007/s00134-013-3030-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
11 Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, Lepore JJ, Cobitz AR. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. J Am Soc Nephrol 2016;27:1234-44. [PMID: 26494831 DOI: 10.1681/ASN.2014111139] [Cited by in Crossref: 100] [Cited by in F6Publishing: 47] [Article Influence: 14.3] [Reference Citation Analysis]
12 Galle JC, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, Di Giulio S, Suranyi MG, Bridges I, Addison J, Farouk M. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrol Dial Transplant 2012;27:2303-11. [PMID: 22140136 DOI: 10.1093/ndt/gfr677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
13 Suttorp MM, Hoekstra T, Mittelman M, Ott I, Franssen CF, Dekker FW. Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients. PLoS One 2013;8:e84848. [PMID: 24391978 DOI: 10.1371/journal.pone.0084848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
14 Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 2014;:CD003895. [PMID: 24872328 DOI: 10.1002/14651858.CD003895.pub3] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
15 den Elzen WP, Willems JM, Westendorp RG, de Craen AJ, Blauw GJ, Ferrucci L, Assendelft WJ, Gussekloo J. Effect of erythropoietin levels on mortality in old age: the Leiden 85-plus Study. CMAJ 2010;182:1953-8. [PMID: 21149533 DOI: 10.1503/cmaj.100374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
16 Cody JD, Hodson EM. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database Syst Rev 2016;:CD003266. [PMID: 26790135 DOI: 10.1002/14651858.CD003266.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
17 Mrkobrada M, Thiessen-Philbrook H, Haynes RB, Iansavichus AV, Rehman F, Garg AX. Need for quality improvement in renal systematic reviews. Clin J Am Soc Nephrol 2008;3:1102-14. [PMID: 18400967 DOI: 10.2215/CJN.04401007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
18 Satirapoj B, Dispan R, Supasyndh O. Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients. Int J Nephrol Renovasc Dis 2017;10:275-83. [PMID: 29033600 DOI: 10.2147/IJNRD.S143731] [Reference Citation Analysis]
19 Elliott S, Tomita D, Endre Z. Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrol 2017;18:14. [PMID: 28077085 DOI: 10.1186/s12882-017-0438-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
20 Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56. [PMID: 22921639 DOI: 10.1053/j.ajkd.2012.07.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
21 Cohen RS, Karlin P, Yushak M, Mancini D, Maurer MS. The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction. Congest Heart Fail 2010;16:96-103. [PMID: 20557328 DOI: 10.1111/j.1751-7133.2009.00135.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]